Skip to main content
PLRZ logo

Polyrizon Ltd. (PLRZ) Stock Price & Analysis

Polyrizon Ltd. (PLRZ) — MoonshotScore 52/100 (Fair band), calculated Oct 5, 2026. Price $9.61 (-6.88%), as of the Oct 2, 2026 trading session; market cap $10.8M.

Educational signal · not a buy or sell recommendation · How to read this

$9.61 −$0.71 (-6.88%) Market Cap $10.8M

Polyrizon Ltd. · PLRZ · NASDAQ

Polyrizon Ltd. is a biotechnology company focused on developing nasal sprays that act as barriers against viruses and allergens.

Price as of Oct 2, 2026

Key Statistics

52 of 100

MoonshotScore v2 · Polyrizon (PLRZ)

Fair
Business Quality Thin (38)
Financial Safety Fortress (93)
Valuation Full (50)
Growth Durability Shrinking (7)
Momentum Quiet (42)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fortress balance sheet, but weak quality and stalling growth. Business Quality: Thin; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Quiet.

  • Altman Z 13.23 · Piotroski F 0
  • ROE -26.1% · ROA -19.2% · current ratio 29.03 · earnings yield -23.6% · free-cash-flow yield -29.0%

Holding back: soft growth

Helping: balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for PLRZ (30 recorded, newest six shown)
RecordedScoreBand
55Fair
55Fair
55Fair
53Fair
53Fair
52Fair

The score was 52 in the stored Oct 4, 2026 snapshot and remains 52 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$9.61
Change on the day-6.88%
52-week range$2.88 – $18.20
Market capitalisation$10.8M
Shares traded on the day56.3K

Price & events

Other perspectives

Council score for Polyrizon (PLRZ): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

9-Factor Breakdown

Revenue Growth Neutral
Gross Margin Weak
Operating Leverage Neutral
Cash Runway Neutral
R&D Intensity Neutral
Insider Activity Weak
Trading Liquidity Neutral
Price Momentum Negative
News Sentiment Neutral

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: May 1, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On May 1, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Oct 5, 2026, except a card that shows its own read date.

Watch the PLRZ film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is Polyrizon (PLRZ), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Polyrizon Ltd. (PLRZ) is listed on NASDAQ. It employs 6 people and is led by Tomer Izraeli. The market values it at $10.8M.

3 · Financial strengths and risks

What are the financial strengths and risks for Polyrizon (PLRZ)?

Short answer

The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z 13.23 · Piotroski F 0. Trailing ratios: ROE -26.1% · ROA -19.2% · current ratio 29.03 · earnings yield -23.6% · free-cash-flow yield -29.0%.

Data-derived red flags

  • Negative return on equity (-26.1%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does Polyrizon compare with its peers?

Short answer

Polyrizon's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
CorMedix Inc. (CRMD) Same industry, near in market value$7.30 Oct 5, 2026$564M94 5-pillar Oct 5, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$10.36 Oct 5, 2026$591M91 5-pillar Oct 5, 2026
Johnson & Johnson (JNJ) Named competitor$254.10 Oct 5, 2026$617B90 5-pillar Oct 5, 2026
MiMedx Group, Inc. (MDXG) Same industry, near in market value$4.67 Oct 5, 2026$669M88 5-pillar Oct 5, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$16.94 Oct 5, 2026$90.6M83 5-pillar Oct 5, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$9.79 Oct 5, 2026$88.2M77 5-pillar Oct 5, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$4.54 Oct 5, 2026$184M76 5-pillar Oct 5, 2026
Merck & Co., Inc. (MRK) Named competitor$140.23 Oct 5, 2026$356B75 5-pillar Oct 5, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.67 Oct 5, 2026$218M73 5-pillar Oct 5, 2026
Niagen Bioscience Inc (NAGE) Same industry, near in market value$2.74 Oct 5, 2026$222M68 5-pillar Oct 5, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$11.18 Oct 5, 2026$626M68 5-pillar Oct 5, 2026
AN2 Therapeutics, Inc. (ANTX) Same industry, near in market value$5.61 Oct 5, 2026$206M67 5-pillar Oct 5, 2026
Polyrizon (PLRZ) — this page$9.61$10.8M52

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
6
Identified insiders
4
Purchases
0
Sales
6
Other transactions
0

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

What has been published about Polyrizon (PLRZ)?

Read these with our analysis →

Common Questions About PLRZ

These answers are editorial: 1 of these 9 answers is drawn from the PLRZ research dossier (written May 4, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for PLRZ?

PLRZ carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is PLRZ a good stock to buy?

Stock Expert AI does not rate PLRZ buy, sell or hold. Polyrizon Ltd. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PLRZ stock price today?

The last price recorded on this page for Polyrizon Ltd. (PLRZ) is $9.61, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about PLRZ stock?

There is currently no available analyst coverage or consensus on Polyrizon Ltd. (PLRZ) stock due to its small market capitalization and limited trading volume.

What are the key factors to evaluate for PLRZ?

Polyrizon Ltd. (PLRZ) holds a MoonshotScore in the moderate range. Polyrizon Ltd. is developing nasal sprays to prevent viral and allergic contact with nasal tissues. Not financial advice.

How frequently does PLRZ data refresh on this page?

PLRZ's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PLRZ's recent stock price performance?

Polyrizon Ltd. (PLRZ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative nasal spray technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PLRZ overvalued or undervalued right now?

Polyrizon Ltd. (PLRZ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of PLRZ?

Fractional-share availability for Polyrizon Ltd. (PLRZ) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources — records for every figure on this page (13 figures)

The 13 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

FMP — 6 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.lastLatest provided price$9.61FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T09:54:49.646Z.
px.changeChange on the day-6.88%FMPFinancial Modeling Prep (FMP) · quote
px.mcapMarket capitalisation$10.8MFMPFinancial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T09:54:49.581Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares.
px.change_absChange on the day, in dollars−$0.71FMPFinancial Modeling Prep (FMP) · quote
px.volumeShares traded on the day56.3KFMPFinancial Modeling Prep (FMP) · quote
own.insidersInsider transactions via FMP6 transactions · 0 purchases, 6 sales, 0 other transactions · 4 identified insiders · most recent available transactionsFMPFinancial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

UNRECORDED — 5 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
fin.scoresDistress and quality screensAltman Z 13.23 · Piotroski F 0UNRECORDEDStored financial-scores observation — Captured 2026-10-03 · Expired observation
fin.ratiosReturn and yield ratios (trailing twelve months)ROE -26.1% · ROA -19.2% · current ratio 29.03 · earnings yield -23.6% · free-cash-flow yield -29.0%—UNRECORDEDStored key metrics — Date unknown
px.range5252-week range$2.88 – $18.20UNRECORDEDStored company-profile observation — Captured 2026-10-05
id.employeesEmployees6UNRECORDEDStored company-profile observation — Captured 2026-10-05
id.ceoChief executiveTomer IzraeliUNRECORDEDStored company-profile observation — Captured 2026-10-05

OURS — 2 facts from Stock Expert AI's own score and rank

OURS facts used on this page
Fact IDFactValue as shownAs ofTierSource
ours.moonshotMoonshotScore v252 of 100 · Fair · pillars 38 / 93 / 50 / 7 / 42OURSStock Expert AI MoonshotScore v2 engine
ours.moonshot_changeMoonshotScore movement52 (stored snapshot Oct 4, 2026) → 52 (current publication computed Oct 5, 2026) (0)OURSStock Expert AI current score publication and immutable score snapshots
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.